Felzartamab |
MOR-03087; TJ-202; HBIB-202; MOR-202 |
Phase 3 Clinical |
Morphosys Ag |
Glomerulonephritis, IGA; Lupus Nephritis; Multiple Myeloma; Glomerulonephritis, Membranous; Rejection of organ transplantation; Lupus Erythematosus, Systemic; Glomerulonephritis |
Details
|
Daratumumab biosimilar (Biocad) |
BCD-264 |
Phase 3 Clinical |
Biocad |
Multiple Myeloma |
Details
|
Mezagitamab |
TAK-079 |
Phase 2 Clinical |
Takeda |
Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Hematologic Neoplasms; Nephrosis; Glomerulonephritis, IGA; Kidney Diseases; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic; Thrombocytopenia; Glomerulonephritis |
Details
|
STI-6129 |
STI-6129; LNDS-1001 |
Phase 2 Clinical |
Sorrento Therapeutics Inc |
Solid tumours; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute |
Details
|
Modakafusp alfa |
TEV-48573; TAK-573 |
Phase 2 Clinical |
Takeda Pharmaceutical Co Ltd |
Neoplasms; Multiple Myeloma; Melanoma |
Details
|
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-T |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma |
Details
|
Anti-CD38 Antibody(Institute of Hematology & Blood Diseases Hospital) |
|
Phase 2 Clinical |
Institute Of Hematology & Blood Diseases Hospital |
Purpura, Thrombocytopenic, Idiopathic; Antiphospholipid Syndrome |
Details
|
ISB-1442 |
ISB 1442; ISB-1442 |
Phase 2 Clinical |
Ichnos Sciences Sa |
Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute |
Details
|
Erzotabart |
GEN-3014 |
Phase 2 Clinical |
Genmab A/S |
Lymphoma, Large B-Cell, Diffuse; Leukemia, Myeloid, Acute |
Details
|
BHV-1100 |
KP-1237; BHV-1100 |
Phase 2 Clinical |
Biohaven Pharmaceuticals Inc, Kleo Pharmaceuticals, PeptiDream Inc |
Multiple Myeloma |
Details
|
Lumrotatug |
CM-313 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma |
Details
|
89Zr-DFO-daratumumab |
|
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center |
Multiple Myeloma |
Details
|
CART-38 |
CART-38 |
Phase 2 Clinical |
The First Affiliated Hospital Of Soochow University |
Leukemia, Myeloid, Acute |
Details
|
64Cu-DOTA-daratumumab |
|
Phase 1 Clinical |
City Of Hope National Medical Center |
Multiple Myeloma |
Details
|
SAR-442257 |
SAR-442257 |
Phase 1 Clinical |
Sanofi |
Neoplasms |
Details
|
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) |
|
Phase 1 Clinical |
Shengyan Pharmaceutical Technology, Wuhan Union Hospital |
Multiple Myeloma |
Details
|
Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) |
CAR-T CD-38 |
Phase 1 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Multiple Myeloma; Leukemia, Myeloid, Acute |
Details
|
SCTC-21-C |
SCTC21C; SCTC-21-C; SCT-C21C |
Phase 1 Clinical |
SinoCelltech Ltd |
Hematologic Neoplasms |
Details
|
CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) |
|
Phase 1 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd, The 920th Hospital Of Joint Logistics Support Force Of PLA |
Leukemia, Myeloid, Acute |
Details
|
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) |
|
Phase 1 Clinical |
Shenzhen Geno-Immune Medical Institute |
Leukemia, Myeloid, Acute |
Details
|
CD38-SADA:177 Lu-DOTA Drug Complex |
|
Phase 1 Clinical |
Y-Mabs Therapeutics Inc |
Lymphoma, Non-Hodgkin |
Details
|
Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering) |
|
Phase 1 Clinical |
Hangzhou Jiuyuan Gene Engineering Co Ltd |
Multiple Myeloma |
Details
|
CART-38(University of Pennsylvania) |
CART-38 |
Phase 1 Clinical |
University Of Pennsylvania |
Multiple Myeloma; Leukemia, Myeloid, Acute |
Details
|
ISB-2001 |
ISB-2001 |
Phase 1 Clinical |
Ichnos Sciences Sa |
Multiple Myeloma |
Details
|
TNB-738 |
TNB-738 |
Phase 1 Clinical |
TeneoFour Inc |
|
Details
|
GBR-1342 |
GBR-1342; ISB-1342 |
Phase 1 Clinical |
Glenmark Pharmaceuticals Ltd |
Multiple Myeloma |
Details
|
XmAb-968 |
XmAb968 |
Phase 1 Clinical |
Xencor Inc |
Hematologic Neoplasms; Leukemia, Promyelocytic, Acute |
Details
|
SG-2501 |
SG-2501 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Hematologic Neoplasms; Lymphoma |
Details
|
XmAb-18968 |
XmAb-18968 |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Leukemia, Myeloid, Acute |
Details
|
CID-103 |
CID-103; TSK011010 |
Phase 1 Clinical |
Tusk Therapeutics Ltd |
Multiple Myeloma |
Details
|
Daratumumab biosimilar (Henlius) |
HLX-15 |
Phase 1 Clinical |
Shanghai Henlius Biologics Co Ltd |
Multiple Myeloma |
Details
|
211At-OKT10-B10 |
|
Phase 1 Clinical |
Fred Hutchinson Cancer Research Center |
Multiple Myeloma |
Details
|
Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) |
Y-150; Y150 |
Phase 1 Clinical |
Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd |
Multiple Myeloma |
Details
|
Recombinant human anti-CD38 momoclonal antibody(Sumgen) |
SG-301; SG301 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic |
Details
|
Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) |
|
Phase 1 Clinical |
Celularity Inc, Sorrento Therapeutics Inc |
Multiple Myeloma |
Details
|
Felzartamab |
MOR-03087; TJ-202; HBIB-202; MOR-202 |
Phase 3 Clinical |
Morphosys Ag |
Glomerulonephritis, IGA; Lupus Nephritis; Multiple Myeloma; Glomerulonephritis, Membranous; Rejection of organ transplantation; Lupus Erythematosus, Systemic; Glomerulonephritis |
Details
|
Daratumumab biosimilar (Biocad) |
BCD-264 |
Phase 3 Clinical |
Biocad |
Multiple Myeloma |
Details
|
Mezagitamab |
TAK-079 |
Phase 2 Clinical |
Takeda |
Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Hematologic Neoplasms; Nephrosis; Glomerulonephritis, IGA; Kidney Diseases; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic; Thrombocytopenia; Glomerulonephritis |
Details
|
STI-6129 |
STI-6129; LNDS-1001 |
Phase 2 Clinical |
Sorrento Therapeutics Inc |
Solid tumours; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute |
Details
|
Modakafusp alfa |
TEV-48573; TAK-573 |
Phase 2 Clinical |
Takeda Pharmaceutical Co Ltd |
Neoplasms; Multiple Myeloma; Melanoma |
Details
|
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-T |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma |
Details
|
Anti-CD38 Antibody(Institute of Hematology & Blood Diseases Hospital) |
|
Phase 2 Clinical |
Institute Of Hematology & Blood Diseases Hospital |
Purpura, Thrombocytopenic, Idiopathic; Antiphospholipid Syndrome |
Details
|
ISB-1442 |
ISB 1442; ISB-1442 |
Phase 2 Clinical |
Ichnos Sciences Sa |
Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute |
Details
|
Erzotabart |
GEN-3014 |
Phase 2 Clinical |
Genmab A/S |
Lymphoma, Large B-Cell, Diffuse; Leukemia, Myeloid, Acute |
Details
|
BHV-1100 |
KP-1237; BHV-1100 |
Phase 2 Clinical |
Biohaven Pharmaceuticals Inc, Kleo Pharmaceuticals, PeptiDream Inc |
Multiple Myeloma |
Details
|
Lumrotatug |
CM-313 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma |
Details
|
89Zr-DFO-daratumumab |
|
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center |
Multiple Myeloma |
Details
|
CART-38 |
CART-38 |
Phase 2 Clinical |
The First Affiliated Hospital Of Soochow University |
Leukemia, Myeloid, Acute |
Details
|
64Cu-DOTA-daratumumab |
|
Phase 1 Clinical |
City Of Hope National Medical Center |
Multiple Myeloma |
Details
|
SAR-442257 |
SAR-442257 |
Phase 1 Clinical |
Sanofi |
Neoplasms |
Details
|
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) |
|
Phase 1 Clinical |
Shengyan Pharmaceutical Technology, Wuhan Union Hospital |
Multiple Myeloma |
Details
|
Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) |
CAR-T CD-38 |
Phase 1 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Multiple Myeloma; Leukemia, Myeloid, Acute |
Details
|
SCTC-21-C |
SCTC21C; SCTC-21-C; SCT-C21C |
Phase 1 Clinical |
SinoCelltech Ltd |
Hematologic Neoplasms |
Details
|
CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) |
|
Phase 1 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd, The 920th Hospital Of Joint Logistics Support Force Of PLA |
Leukemia, Myeloid, Acute |
Details
|
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) |
|
Phase 1 Clinical |
Shenzhen Geno-Immune Medical Institute |
Leukemia, Myeloid, Acute |
Details
|
CD38-SADA:177 Lu-DOTA Drug Complex |
|
Phase 1 Clinical |
Y-Mabs Therapeutics Inc |
Lymphoma, Non-Hodgkin |
Details
|
Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering) |
|
Phase 1 Clinical |
Hangzhou Jiuyuan Gene Engineering Co Ltd |
Multiple Myeloma |
Details
|
CART-38(University of Pennsylvania) |
CART-38 |
Phase 1 Clinical |
University Of Pennsylvania |
Multiple Myeloma; Leukemia, Myeloid, Acute |
Details
|
ISB-2001 |
ISB-2001 |
Phase 1 Clinical |
Ichnos Sciences Sa |
Multiple Myeloma |
Details
|
TNB-738 |
TNB-738 |
Phase 1 Clinical |
TeneoFour Inc |
|
Details
|
GBR-1342 |
GBR-1342; ISB-1342 |
Phase 1 Clinical |
Glenmark Pharmaceuticals Ltd |
Multiple Myeloma |
Details
|
XmAb-968 |
XmAb968 |
Phase 1 Clinical |
Xencor Inc |
Hematologic Neoplasms; Leukemia, Promyelocytic, Acute |
Details
|
SG-2501 |
SG-2501 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Hematologic Neoplasms; Lymphoma |
Details
|
XmAb-18968 |
XmAb-18968 |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Leukemia, Myeloid, Acute |
Details
|
CID-103 |
CID-103; TSK011010 |
Phase 1 Clinical |
Tusk Therapeutics Ltd |
Multiple Myeloma |
Details
|
Daratumumab biosimilar (Henlius) |
HLX-15 |
Phase 1 Clinical |
Shanghai Henlius Biologics Co Ltd |
Multiple Myeloma |
Details
|
211At-OKT10-B10 |
|
Phase 1 Clinical |
Fred Hutchinson Cancer Research Center |
Multiple Myeloma |
Details
|
Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) |
Y-150; Y150 |
Phase 1 Clinical |
Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd |
Multiple Myeloma |
Details
|
Recombinant human anti-CD38 momoclonal antibody(Sumgen) |
SG-301; SG301 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic |
Details
|
Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) |
|
Phase 1 Clinical |
Celularity Inc, Sorrento Therapeutics Inc |
Multiple Myeloma |
Details
|